Results 331 to 340 of about 3,018,484 (379)

Transapical Closure of Re-entry Tear in Aortic Dissection With the Off-Label Use of a Gore Cardioform Septal Occluder Using 3D-Printed Simulation. [PDF]

CJC Open
Huber C, Vaisière L, Müller H, Ellenberger C, Cikirikcioglu M, Vallée JP, Noble S.   +6 more
europepmc   +1 more source

Off-label use of cannabidiol in genetic epileptic and developmental encephalopathies: A case report

Elisa Mannini, Francesco Misirocchi, Stefania Lazzari, Giulia Balella, Dario Bottignole, Maddalena Frapporti, Lucia Zinno, Irene Florindo, Liborio Parrino, Carlotta Mutti   +9 more
openalex   +1 more source

Off-label use of recombinant adjuvanted Herpes Zoster vaccine in a 10-year-old high-risk patient affected by epidermolysis bullosa: A case report. [PDF]

Hum Vaccin Immunother
Palmieri C, Noviello C, Moscara L, Stefanizzi P, Berti I, Tafuri S, Arbo A.   +6 more
europepmc   +1 more source

Off-label drug use

, 2009
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Public Interest in the Off-Label Use of Glucagon-Like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends Analysis.

Aesthetic surgery journal, 2023
BACKGROUND Glucagon-like peptide 1 (GLP-1) agonists are a drug class used for the treatment of diabetes that have recently gained FDA approval for medical management of obesity.
Sabrina H Han, Rachel Safeek, Kyle M Ockerman, Nicky S. Trieu, Patricia Mars, Audrey Klenke, H. Furnas, Sarah Sorice-Virk   +7 more
semanticscholar   +1 more source

Expert Guidance on Off-Label Use of Hybrid Closed-Loop Therapy in Pregnancies Complicated by Diabetes

Diabetes Technology & Therapeutics, 2023
Automated insulin delivery (AID) systems have established benefits in terms of glycemic control, health outcomes, and quality of life and are strongly recommended for people with type 1 diabetes outside of pregnancy.
Emily D. Szmuilowicz, C. Levy, Elizabeth O. Buschur, Sarit Polsky   +3 more
semanticscholar   +1 more source

Off‐label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature

Haemophilia, 2021
Since the approval of emicizumab, a bispecific, factor VIII‐mimetic antibody, for use in persons with congenital haemophilia A in 2018, there have been increasing case reports and case series of off‐label use of emicizumab in other bleeding disorders ...
V. Thomas, Mouhamed Yazan Abou-Ismail, Ming Y. Lim   +2 more
semanticscholar   +1 more source

Off‐label uses of ustekinumab

Dermatologic Therapy, 2022
Ustekinumab (brand name Stelara®) is a human interleukin-12 and -23 antagonist and has been indicated for the treatments of moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. This review aims to synthesize and interpret the literature evaluating the off-label uses of ustekinumab.
Lihua Ye, Zhenfei Wu, Changrong Li, Xiaoxia Zhao, Mengjie Wan, Li Wang   +5 more
openaire   +2 more sources

A Clinical Overview of Off-label Use of Gabapentinoid Drugs.

JAMA Internal Medicine, 2019
Background The gabapentinoid drugs gabapentin and pregabalin were originally developed as antiseizure drugs but now are prescribed mainly for treatment of pain.
Christopher W. Goodman, A. Brett
semanticscholar   +1 more source